Richard Lean
Impact in
- Infectious Diseases top 0.5%
- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
- Genetics top 5%
- Genetic Associations and Epidemiology
Papers in
-
- COVID-19 Clinical Research Studies 16
- SARS-CoV-2 and COVID-19 Research 2
- Genetics 7
- Genetic Associations and Epidemiology 7
- Journals
- The Lancet (6 papers)JAMA (5 papers)Nature (4 papers)EClinicalMedicine (1 paper)The Lancet Diabetes & Endocrinology (1 paper)
- Partner nations
- United KingdomVietnamAustralia
In The Last Decade
Richard Lean
22 papers receiving 3.2k citations
Richard Lean's Hit Papers
Peers
Comparison fields: 5 of 102
- Infectious Diseases 2.1k
- Genetics 531
- Applied Microbiology and Biotechnology 35
- Internal Medicine 45
- Neurology 116
Countries citing papers authored by Richard Lean
This map shows the geographic impact of Richard Lean's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard Lean with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard Lean more than expected).
Fields of papers citing papers by Richard Lean
This network shows the impact of papers produced by Richard Lean. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard Lean. The network helps show where Richard Lean may publish in the future.
No co-authors to show.
All Works
Showing the 20 most-cited of 23 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Mapping the human genetic architecture of COVID-19 Hit paper breakdown → | 2021 | 656 |
| 2 | Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2021 | 411 |
| 3 | Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial Hit paper breakdown → | 2021 | 393 |
| 4 | Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2022 | 282 |
| 5 | Whole-genome sequencing reveals host factors underlying critical COVID-19 Hit paper breakdown → | 2022 | 233 |
| 6 | Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis Hit paper breakdown → | 2022 | 231 |
| 7 | 2021 | 213 | |
| 8 | 2021 | 166 | |
| 9 | GWAS and meta-analysis identifies 49 genetic variants underlying critical COVID-19 Hit paper breakdown → | 2023 | 125 |
| 10 | 2022 | 105 | |
| 11 | 2022 | 100 | |
| 12 | Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2023 | 84 |
| 13 | 2021 | 72 | |
| 14 | 2023 | 60 | |
| 15 | 2023 | 46 | |
| 16 | 2023 | 34 | |
| 17 | 2021 | 26 | |
| 18 | 2023 | 25 | |
| 19 | 2024 | 24 | |
| 20 | 2024 | 8 |
About Richard Lean
Richard Lean is a scholar working on Infectious Diseases, Genetics, Nutrition and Dietetics, Surgery and Nuclear Energy and Engineering, having authored 23 papers that have together received 3.3k indexed citations. Recurring topics across this work include COVID-19 Clinical Research Studies (16 papers), Genetic Associations and Epidemiology (7 papers), SARS-CoV-2 and COVID-19 Research (2 papers), Vitamin C and Antioxidants Research (1 paper) and Kawasaki Disease and Coronary Complications (1 paper). The work is most often cited by research in Infectious Diseases (2.1k citations), Genetics (531 citations), Applied Microbiology and Biotechnology (35 citations), Internal Medicine (45 citations) and Neurology (116 citations). Richard Lean has collaborated with scholars based in United Kingdom, Vietnam and Australia. Their work appears in journals such as The Lancet, JAMA, Nature, EClinicalMedicine and The Lancet Diabetes & Endocrinology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.